Frederik Wenz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Frederik Wenz has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Frank Anton Giordano
Department of Radiation Oncology, Medical Faculty Mannheim, University Medicine Mannheim, Heidelberg University, Mannheim, Germany; DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany; Mannheim Institute for Intelligent Systems in Medicine, Medical Faculty, Heidelberg University, Mannheim, Germany
3 shared publications - Benjamin Tuschy
Department of Gynecology and Obstetrics, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
2 shared publications - Carsten Herskind
Cellular and Molecular Radiation Oncology Lab, Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
2 shared publications - Daniel Buergy
Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
2 shared publications - Elena Sperk
Mannheim Cancer Center, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
2 shared publications - Fabian Bürkin
University Medical Center Freiburg
2 shared publications
Latest Publications
- Open Access
- 4 December 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1)
Intraoperative radiotherapy in elderly patients with breast cancer: long-term follow-up results of the prospective phase II trial TARGIT-E
Background: Whole-breast radiotherapy (WBRT) after breast-conserving surgery (BCS) in older patients can be challenging due to the increased presence of comorbidities, comedication, the presence of a pacemaker or difficulties in traveling to treatment every day. Challenging times, such as the pandemic, can also lead to RT not being performed despite the indication. Very short treatment regimens are therefor of special interest in this population reducing overall treatment time and radiation exposure. TARGIT-E is a phase II trial investigating intraoperative radiotherapy (IORT) during BCS in elderly patients. We report long-term follow-up results of TARGIT-E. Methods: Patients with BC (≥ 70 years, cT1-2, cN0, M0) were enrolled at 28 European centers. A single dose of IORT (20 Gy) was given during BCS. Additional postoperative WBRT was applied if risk factors were present in final histopathology. Primary outcome was local recurrence-free rate (RFR) using the Kaplan–Meier-method. Late toxicities were assessed by LENT-SOMA criteria, and cosmetic outcomes were graded using BCCT.core software. Results: In 591 patients (median follow-up 5.4 years) RFR was 97.6% (CI: 96.1, 99.2) and 97.1% (CI: 95.2, 98.9) after 5 and 7 years. Overall survival was 96.2% (CI: 94.4, 98.1) and 91.8% (CI: 91.5, 92.1) after 5 and 7 years. We observed either no or mild late toxicities after 7 years. The most frequent toxicities were fibrosis (grade II-III: 15.7%), pain (grade II-III: 3.3%), retractions (grade I: 30%), and teleangiectasia (grade I: 8.9%). Chronic higher-grade fibrosis was seen in 10% and chronic pain in 2% after 7 years in patients treated with IORT only. Cosmetic outcomes were excellent or good for most patients. Conclusions: The high local control rate and overall survival in combination with low occurrence of late toxicities over 7 years demonstrate that targeted intraoperative radiotherapy is a fast, simple and feasible method during breast-conserving surgery for selected elderly patients. Trial registration: TARGIT E was prospectively registered at ClinicalTrials.gov with the number NCT01299987 (date: 18 February 2011).
- 4 December 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1)
Open AccessIntraoperative radiotherapy in elderly patients with breast cancer: long-term follow-up results of the prospective phase II trial TARGIT-E
Background: Whole-breast radiotherapy (WBRT) after breast-conserving surgery (BCS) in older patients can be challenging due to the increased presence of comorbidities, comedication, the presence of a pacemaker or difficulties in traveling to treatment every day. Challenging times, such as the pandemic, can also lead to RT not being performed despite the indication. Very short treatment regimens are therefor of special interest in this population reducing overall treatment time and radiation exposure. TARGIT-E is a phase II trial investigating intraoperative radiotherapy (IORT) during BCS in elderly patients. We report long-term follow-up results of TARGIT-E. Methods: Patients with BC (≥ 70 years, cT1-2, cN0, M0) were enrolled at 28 European centers. A single dose of IORT (20 Gy) was given during BCS. Additional postoperative WBRT was applied if risk factors were present in final histopathology. Primary outcome was local recurrence-free rate (RFR) using the Kaplan–Meier-method. Late toxicities were assessed by LENT-SOMA criteria, and cosmetic outcomes were graded using BCCT.core software. Results: In 591 patients (median follow-up 5.4 years) RFR was 97.6% (CI: 96.1, 99.2) and 97.1% (CI: 95.2, 98.9) after 5 and 7 years. Overall survival was 96.2% (CI: 94.4, 98.1) and 91.8% (CI: 91.5, 92.1) after 5 and 7 years. We observed either no or mild late toxicities after 7 years. The most frequent toxicities were fibrosis (grade II-III: 15.7%), pain (grade II-III: 3.3%), retractions (grade I: 30%), and teleangiectasia (grade I: 8.9%). Chronic higher-grade fibrosis was seen in 10% and chronic pain in 2% after 7 years in patients treated with IORT only. Cosmetic outcomes were excellent or good for most patients. Conclusions: The high local control rate and overall survival in combination with low occurrence of late toxicities over 7 years demonstrate that targeted intraoperative radiotherapy is a fast, simple and feasible method during breast-conserving surgery for selected elderly patients. Trial registration: TARGIT E was prospectively registered at ClinicalTrials.gov with the number NCT01299987 (date: 18 February 2011).
- Open Access
- 14 August 2024
- Published by Springer Nature in Die Chirurgie
- Vol. 96 (4) , 316-321
Reformvorhaben „Gelegenheits-Onkochirurgie“
Zusammenfassung: Hintergrund: Nach wie vor stellen Krebsleiden die zweithäufigste Todesursache in Deutschland dar. Leistungssteuerung und Spezialisierungskonzepte in der Medizin bergen Potenziale, die Versorgung und die Überlebenschancen von Patientinnen und Patienten positiv zu beeinflussen. Ziel der Arbeit: Aus der Gesetzesinitiative im Rahmen des KHVVG resultiert aus der Perspektive des UKF eine ganze Reihe medizinstrategischer Implikationen. Diese Arbeit erläutert und diskutiert die Hintergründe, Ziele und Inhalte des Reformvorhabens „Gelegenheits-Onkochirurgie“ und gibt Perspektiven auf strategische Handlungsfelder. Material und Methoden: Analyse und Interpretation des Entwurfs eines Gesetzes zur Verbesserung der Versorgungsqualität im Krankenhaus und zur Reform der Vergütungsstrukturen (Gesetzentwurf der Bundesregierung). Ergebnisse: Aus Sicht des UKF sollten Krankenhäuser frühestmöglich und proaktiv Kooperationsgespräche mit benachbarten Krankenhäusern zur Gestaltung der regionalen Gesundheitsversorgung führen mit den Zielen, die lokale Allokation onkologischer Patientinnen und Patienten im Sinne einer bestmöglichen Behandlung abzubilden, den Verlust von Patienten an den betroffenen Standorten abzufedern sowie den Patientenaufwuchs bei den Einrichtungen, die weiterhin onkochirurgisch versorgen werden, vorzubereiten. Diskussion: Das noch laufende Gesetzgebungsverfahren sowie der Umstand, dass eine belastbare Analyse der relevanten Leistungsbereiche erst im ersten Halbjahr 2025 für Krankenhäuser möglich sein wird, stellt die Einrichtungen vor besondere Herausforderungen in der strategischen Planung ihrer Aktivitäten. Die im Rahmen dieser Arbeit dargestellten Lücken im Gesetzesvorhaben sollten dringend geschlossen werden, um die Ziele des Vorhabens nicht zu konterkarieren und die im System verbleibenden Leistungserbringer bei ihren Vorbereitungen zu unterstützen.
- 14 August 2024
- Published by Springer Nature in Die Chirurgie
- Vol. 96 (4) , 316-321
Open AccessReformvorhaben „Gelegenheits-Onkochirurgie“
Zusammenfassung: Hintergrund: Nach wie vor stellen Krebsleiden die zweithäufigste Todesursache in Deutschland dar. Leistungssteuerung und Spezialisierungskonzepte in der Medizin bergen Potenziale, die Versorgung und die Überlebenschancen von Patientinnen und Patienten positiv zu beeinflussen. Ziel der Arbeit: Aus der Gesetzesinitiative im Rahmen des KHVVG resultiert aus der Perspektive des UKF eine ganze Reihe medizinstrategischer Implikationen. Diese Arbeit erläutert und diskutiert die Hintergründe, Ziele und Inhalte des Reformvorhabens „Gelegenheits-Onkochirurgie“ und gibt Perspektiven auf strategische Handlungsfelder. Material und Methoden: Analyse und Interpretation des Entwurfs eines Gesetzes zur Verbesserung der Versorgungsqualität im Krankenhaus und zur Reform der Vergütungsstrukturen (Gesetzentwurf der Bundesregierung). Ergebnisse: Aus Sicht des UKF sollten Krankenhäuser frühestmöglich und proaktiv Kooperationsgespräche mit benachbarten Krankenhäusern zur Gestaltung der regionalen Gesundheitsversorgung führen mit den Zielen, die lokale Allokation onkologischer Patientinnen und Patienten im Sinne einer bestmöglichen Behandlung abzubilden, den Verlust von Patienten an den betroffenen Standorten abzufedern sowie den Patientenaufwuchs bei den Einrichtungen, die weiterhin onkochirurgisch versorgen werden, vorzubereiten. Diskussion: Das noch laufende Gesetzgebungsverfahren sowie der Umstand, dass eine belastbare Analyse der relevanten Leistungsbereiche erst im ersten Halbjahr 2025 für Krankenhäuser möglich sein wird, stellt die Einrichtungen vor besondere Herausforderungen in der strategischen Planung ihrer Aktivitäten. Die im Rahmen dieser Arbeit dargestellten Lücken im Gesetzesvorhaben sollten dringend geschlossen werden, um die Ziele des Vorhabens nicht zu konterkarieren und die im System verbleibenden Leistungserbringer bei ihren Vorbereitungen zu unterstützen.
- Open Access
Acute and Long-Term Toxicity after Planned Intraoperative Boost and Whole Breast Irradiation in High-Risk Patients with Breast Cancer—Results from the Targeted Intraoperative Radiotherapy Boost Quality Registry (TARGIT BQR)
In the context of breast cancer treatment optimization, this study prospectively examines the feasibility and outcomes of utilizing intraoperative radiotherapy (IORT) as a boost in combination with standard external beam radiotherapy (EBRT) for high-risk patients. Different guidelines recommend such a tumor bed boost in addition to whole breast irradiation with EBRT for patients with risk factors for local breast cancer recurrence. The TARGIT BQR (NCT01440010) is a prospective, multicenter registry study aimed at ensuring the quality of clinical outcomes. It provides, for the first time, data from a large cohort with a detailed assessment of acute and long-term toxicity following an IORT boost using low-energy X-rays. Inclusion criteria encompassed tumors up to 3.5 cm in size and preoperative indications for a boost. The IORT boost, administered immediately after tumor resection, delivered a single dose of 20 Gy. EBRT and systemic therapy adhered to local tumor board recommendations. Follow-up for toxicity assessment (LENT SOMA criteria: fibrosis, teleangiectasia, retraction, pain, breast edema, lymphedema, hyperpigmentation, ulceration) took place before surgery, 6 weeks to 90 days after EBRT, 6 months after IORT, and then annually using standardized case report forms (CRFs). Between 2011 and 2020, 1133 patients from 10 centers were preoperatively enrolled. The planned IORT boost was conducted in 90%, and EBRT in 97% of cases. Median follow-up was 32 months (range 1–120, 20.4% dropped out), with a median age of 61 years (range 30–90). No acute grade 3 or 4 toxicities were observed. Acute side effects included erythema grade 1 or 2 in 4.4%, palpable seroma in 9.1%, punctured seroma in 0.3%, and wound healing disorders in 2.1%. Overall, chronic teleangiectasia of any grade occurred in 16.2%, fibrosis grade ≥ 2 in 14.3%, pain grade ≥ 2 in 3.4%, and hyperpigmentation in 1.1%. In conclusion, a tumor bed boost through IORT using low-energy X-rays is a swift and feasible method that demonstrates low rates in terms of acute or long-term toxicity profiles in combination with whole breast irradiation.
Open AccessAcute and Long-Term Toxicity after Planned Intraoperative Boost and Whole Breast Irradiation in High-Risk Patients with Breast Cancer—Results from the Targeted Intraoperative Radiotherapy Boost Quality Registry (TARGIT BQR)
In the context of breast cancer treatment optimization, this study prospectively examines the feasibility and outcomes of utilizing intraoperative radiotherapy (IORT) as a boost in combination with standard external beam radiotherapy (EBRT) for high-risk patients. Different guidelines recommend such a tumor bed boost in addition to whole breast irradiation with EBRT for patients with risk factors for local breast cancer recurrence. The TARGIT BQR (NCT01440010) is a prospective, multicenter registry study aimed at ensuring the quality of clinical outcomes. It provides, for the first time, data from a large cohort with a detailed assessment of acute and long-term toxicity following an IORT boost using low-energy X-rays. Inclusion criteria encompassed tumors up to 3.5 cm in size and preoperative indications for a boost. The IORT boost, administered immediately after tumor resection, delivered a single dose of 20 Gy. EBRT and systemic therapy adhered to local tumor board recommendations. Follow-up for toxicity assessment (LENT SOMA criteria: fibrosis, teleangiectasia, retraction, pain, breast edema, lymphedema, hyperpigmentation, ulceration) took place before surgery, 6 weeks to 90 days after EBRT, 6 months after IORT, and then annually using standardized case report forms (CRFs). Between 2011 and 2020, 1133 patients from 10 centers were preoperatively enrolled. The planned IORT boost was conducted in 90%, and EBRT in 97% of cases. Median follow-up was 32 months (range 1–120, 20.4% dropped out), with a median age of 61 years (range 30–90). No acute grade 3 or 4 toxicities were observed. Acute side effects included erythema grade 1 or 2 in 4.4%, palpable seroma in 9.1%, punctured seroma in 0.3%, and wound healing disorders in 2.1%. Overall, chronic teleangiectasia of any grade occurred in 16.2%, fibrosis grade ≥ 2 in 14.3%, pain grade ≥ 2 in 3.4%, and hyperpigmentation in 1.1%. In conclusion, a tumor bed boost through IORT using low-energy X-rays is a swift and feasible method that demonstrates low rates in terms of acute or long-term toxicity profiles in combination with whole breast irradiation.
- Open Access
- 13 November 2023
- Published by Springer Nature in Die Onkologie
- Vol. 30 (5) , 339-346
Anwendungen künstlicher Intelligenz in der Onkologie: Möglichkeiten, Machbarkeit und regulatorische Herausforderungen
Zusammenfassung: Die Integration von künstlicher Intelligenz (KI) in die Onkologie verspricht eine Revolution in Diagnose, Behandlung und Forschung. Es werden verschiedene Anwendungen betrachtet, wobei auf die Belastung und den Burnout von Onkologen eingegangen wird. Die Potenziale werden umfassend erörtert, angefangen bei der Prävention durch Wearables und KI-gestützte Analyse von Gesundheitsdaten bis zur personalisierten Behandlungsplanung und beschleunigten Medikamentenentwicklung. Ein Fokus liegt auf AlphaFold, einer KI-Anwendung für Protein-Folding. Die Verwaltung von Patientendaten und die Erstellung von Befundberichten werden durch KI optimiert, wobei Suchmaschinen und Large Language Models (LLM) eine herausragende Rolle spielen. Die zunehmende Spezialisierung von LLM, etwa in der medizinischen Textgenerierung, verdeutlicht die wachsende Bedeutung. Die Machbarkeit solcher KI-Anwendungen ist gegeben, wobei Ressourcen- und Schulungsbedarf für das medizinische Personal berücksichtigt werden müssen. Kommerzielle Organisationen, wie DeepMind, spielen eine wichtige Rolle in der Umsetzung von KI in die klinische Praxis. Regulatorische Herausforderungen werden diskutiert, einschließlich Datenschutz, Qualitätskontrolle, Haftung und ethische Aspekte. Der European Health Data Space (EHDS) ist eine vielversprechende Initiative für die Förderung des sicheren Datenaustauschs innerhalb der EU. Insgesamt kann KI bedeutende Fortschritte in der Onkologie ermöglichen. Die regulatorischen Herausforderungen erfordern jedoch Sorgfalt und Aufmerksamkeit, um eine ethisch verantwortungsvolle und sichere Implementierung sicherzustellen. KI-Anwendungen können die Krebsversorgung verbessern, die Patientenversorgung revolutionieren und die Arbeitsbelastung für medizinisches Personal reduzieren.
- 13 November 2023
- Published by Springer Nature in Die Onkologie
- Vol. 30 (5) , 339-346
Open AccessAnwendungen künstlicher Intelligenz in der Onkologie: Möglichkeiten, Machbarkeit und regulatorische Herausforderungen
Zusammenfassung: Die Integration von künstlicher Intelligenz (KI) in die Onkologie verspricht eine Revolution in Diagnose, Behandlung und Forschung. Es werden verschiedene Anwendungen betrachtet, wobei auf die Belastung und den Burnout von Onkologen eingegangen wird. Die Potenziale werden umfassend erörtert, angefangen bei der Prävention durch Wearables und KI-gestützte Analyse von Gesundheitsdaten bis zur personalisierten Behandlungsplanung und beschleunigten Medikamentenentwicklung. Ein Fokus liegt auf AlphaFold, einer KI-Anwendung für Protein-Folding. Die Verwaltung von Patientendaten und die Erstellung von Befundberichten werden durch KI optimiert, wobei Suchmaschinen und Large Language Models (LLM) eine herausragende Rolle spielen. Die zunehmende Spezialisierung von LLM, etwa in der medizinischen Textgenerierung, verdeutlicht die wachsende Bedeutung. Die Machbarkeit solcher KI-Anwendungen ist gegeben, wobei Ressourcen- und Schulungsbedarf für das medizinische Personal berücksichtigt werden müssen. Kommerzielle Organisationen, wie DeepMind, spielen eine wichtige Rolle in der Umsetzung von KI in die klinische Praxis. Regulatorische Herausforderungen werden diskutiert, einschließlich Datenschutz, Qualitätskontrolle, Haftung und ethische Aspekte. Der European Health Data Space (EHDS) ist eine vielversprechende Initiative für die Förderung des sicheren Datenaustauschs innerhalb der EU. Insgesamt kann KI bedeutende Fortschritte in der Onkologie ermöglichen. Die regulatorischen Herausforderungen erfordern jedoch Sorgfalt und Aufmerksamkeit, um eine ethisch verantwortungsvolle und sichere Implementierung sicherzustellen. KI-Anwendungen können die Krebsversorgung verbessern, die Patientenversorgung revolutionieren und die Arbeitsbelastung für medizinisches Personal reduzieren.
- 29 January 2022
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 168, 69-74
Radiotherapy and newly approved cancer drugs – A quantitative analysis of registered protocols for drugs approved for the treatment of solid tumors
- 29 January 2022
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 168, 69-74
Radiotherapy and newly approved cancer drugs – A quantitative analysis of registered protocols for drugs approved for the treatment of solid tumors
- 1 January 2022
- Published by Springer Nature
- p. 1-5
Intraoperative Strahlentherapie (IORT)
- Open Access
- 24 June 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (13) , 6778
Intracellular Delivery of Doxorubicin by Iron Oxide-Based Nano-Constructs Increases Clonogenic Inactivation of Ionizing Radiation in HeLa Cells
In this study, we determined the potential of polyethylene glycol-encapsulated iron oxide nanoparticles (IONPCO) for the intracellular delivery of the chemotherapeutic doxorubicin (IONPDOX) to enhance the cytotoxic effects of ionizing radiation. The biological effects of IONP and X-ray irradiation (50 kV and 6 MV) were determined in HeLa cells using the colony formation assay (CFA) and detection of γH2AX foci. Data are presented as mean ± SEM. IONP were efficiently internalized by HeLa cells. IONPCO radiomodulating effect was dependent on nanoparticle concentration and photon energy. IONPCO did not radiosensitize HeLa cells with 6 MV X-rays, yet moderately enhanced cellular radiosensitivity to 50 kV X-rays (DMFSF0.1 = 1.13 ± 0.05 (p = 0.01)). IONPDOX did enhance the cytotoxicity of 6 MV X-rays (DMFSF0.1 = 1.3 ± 0.1; p = 0.0005). IONP treatment significantly increased γH2AX foci induction without irradiation. Treatment of HeLa cells with IONPCO resulted in a radiosensitizing effect for low-energy X-rays, while exposure to IONPDOX induced radiosensitization compared to IONPCO in cells irradiated with 6 MV X-rays. The effect did not correlate with the induction of γH2AX foci. Given these results, IONP are promising candidates for the controlled delivery of DOX to enhance the cytotoxic effects of ionizing radiation.
- 24 June 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (13) , 6778
Open AccessIntracellular Delivery of Doxorubicin by Iron Oxide-Based Nano-Constructs Increases Clonogenic Inactivation of Ionizing Radiation in HeLa Cells
In this study, we determined the potential of polyethylene glycol-encapsulated iron oxide nanoparticles (IONPCO) for the intracellular delivery of the chemotherapeutic doxorubicin (IONPDOX) to enhance the cytotoxic effects of ionizing radiation. The biological effects of IONP and X-ray irradiation (50 kV and 6 MV) were determined in HeLa cells using the colony formation assay (CFA) and detection of γH2AX foci. Data are presented as mean ± SEM. IONP were efficiently internalized by HeLa cells. IONPCO radiomodulating effect was dependent on nanoparticle concentration and photon energy. IONPCO did not radiosensitize HeLa cells with 6 MV X-rays, yet moderately enhanced cellular radiosensitivity to 50 kV X-rays (DMFSF0.1 = 1.13 ± 0.05 (p = 0.01)). IONPDOX did enhance the cytotoxicity of 6 MV X-rays (DMFSF0.1 = 1.3 ± 0.1; p = 0.0005). IONP treatment significantly increased γH2AX foci induction without irradiation. Treatment of HeLa cells with IONPCO resulted in a radiosensitizing effect for low-energy X-rays, while exposure to IONPDOX induced radiosensitization compared to IONPCO in cells irradiated with 6 MV X-rays. The effect did not correlate with the induction of γH2AX foci. Given these results, IONP are promising candidates for the controlled delivery of DOX to enhance the cytotoxic effects of ionizing radiation.
- Open Access
Pandemic-Driven Development of a Medical-Grade, Economic and Decentralized Applicable Polyolefin Filament for Additive Fused Filament Fabrication
A polyolefin with certified biocompatibility according to USP class VI was used by our group as feedstock for filament-based 3D printing to meet the highest medical standards in order to print personal protective equipment for our university hospital during the ongoing pandemic. Besides the chemical resistance and durability, as well as the ability to withstand steam sterilization, this polypropylene (PP) copolymer is characterized by its high purity, as achieved by highly efficient and selective catalytic polymerization. As the PP copolymer is suited to be printed with all common printers in fused filament fabrication (FFF), it offers an eco-friendly cost–benefit ratio, even for large-scale production. In addition, a digital workflow was established focusing on common desktop FFF printers in the medical sector. It comprises the simulation-based optimization of personalized print objects, considering the inherent material properties such as warping tendency, through to validation of the process chain by 3D scanning, sterilization, and biocompatibility analysis of the printed part. This combination of digital data processing and 3D printing with a sustainable and medically certified material showed great promise in establishing decentralized additive manufacturing in everyday hospital life to meet peaks in demand, supply bottlenecks, and enhanced personalized patient treatment.
Open AccessPandemic-Driven Development of a Medical-Grade, Economic and Decentralized Applicable Polyolefin Filament for Additive Fused Filament Fabrication
A polyolefin with certified biocompatibility according to USP class VI was used by our group as feedstock for filament-based 3D printing to meet the highest medical standards in order to print personal protective equipment for our university hospital during the ongoing pandemic. Besides the chemical resistance and durability, as well as the ability to withstand steam sterilization, this polypropylene (PP) copolymer is characterized by its high purity, as achieved by highly efficient and selective catalytic polymerization. As the PP copolymer is suited to be printed with all common printers in fused filament fabrication (FFF), it offers an eco-friendly cost–benefit ratio, even for large-scale production. In addition, a digital workflow was established focusing on common desktop FFF printers in the medical sector. It comprises the simulation-based optimization of personalized print objects, considering the inherent material properties such as warping tendency, through to validation of the process chain by 3D scanning, sterilization, and biocompatibility analysis of the printed part. This combination of digital data processing and 3D printing with a sustainable and medically certified material showed great promise in establishing decentralized additive manufacturing in everyday hospital life to meet peaks in demand, supply bottlenecks, and enhanced personalized patient treatment.
- Open Access
Switching from algorithm-based to universal admission screening for COVID-19 in hospital settings
Detection of COVID-19 positive cases on admission to hospitals is crucial to protect patients and staff at the same time. While universal admission screening can prevent more undetected introductions than the algorithm-based screening, which preselects patient based on their symptoms and exposure, it is a more costly strategy as it involves testing a large number of patients. We construct a simple tool to help determine when the benefit of additionally found cases outweighs the cost of the additionally tested patients, based on the numbers of patients to be screened in an acceptable time span to find an additional case when screening all admitted patients.
Open AccessSwitching from algorithm-based to universal admission screening for COVID-19 in hospital settings
Detection of COVID-19 positive cases on admission to hospitals is crucial to protect patients and staff at the same time. While universal admission screening can prevent more undetected introductions than the algorithm-based screening, which preselects patient based on their symptoms and exposure, it is a more costly strategy as it involves testing a large number of patients. We construct a simple tool to help determine when the benefit of additionally found cases outweighs the cost of the additionally tested patients, based on the numbers of patients to be screened in an acceptable time span to find an additional case when screening all admitted patients.
- Open Access
Navigating hospitals safely through the COVID-19 epidemic tide: predicting case load for adjusting bed capacity
Background: The pressures exerted by the pandemic of COVID-19 pose an unprecedented demand on health care services. Hospitals become rapidly overwhelmed when patients requiring life-saving support outpace available capacities. We here describe methods used by a university hospital to forecast caseloads and time to peak incidence. Methods: We developed a set of models to forecast incidence among the hospital catchment population and describe the COVID-19 patient hospital care-path. The first forecast utilized data from antecedent allopatric epidemics and parameterized the care path model according to expert opinion (static model). Once sufficient local data were available, trends for the time dependent effective reproduction number were fitted and the care-path was parameterized using hazards for real patient admission, referrals, and discharge (dynamic model). Results: The static model, deployed before the epidemic, exaggerated the bed occupancy (general wards 116 forecasted vs 66 observed, ICU 47 forecasted vs 34 observed) and predicted the peak too late (general ward forecast April 9, observed April 8, ICU forecast April 19, observed April 8). After April 5, the dynamic model could be run daily and precision improved with increasing availability of empirical local data. Conclusions: The models provided data-based guidance in the preparation and allocation of critical resources of a university hospital well in advance of the epidemic surge, despite overestimating the service demand. Overestimates should resolve when population contact pattern before and during restrictions can be taken into account, but for now they may provide an acceptable safety margin for preparing during times of uncertainty.
Open AccessNavigating hospitals safely through the COVID-19 epidemic tide: predicting case load for adjusting bed capacity
Background: The pressures exerted by the pandemic of COVID-19 pose an unprecedented demand on health care services. Hospitals become rapidly overwhelmed when patients requiring life-saving support outpace available capacities. We here describe methods used by a university hospital to forecast caseloads and time to peak incidence. Methods: We developed a set of models to forecast incidence among the hospital catchment population and describe the COVID-19 patient hospital care-path. The first forecast utilized data from antecedent allopatric epidemics and parameterized the care path model according to expert opinion (static model). Once sufficient local data were available, trends for the time dependent effective reproduction number were fitted and the care-path was parameterized using hazards for real patient admission, referrals, and discharge (dynamic model). Results: The static model, deployed before the epidemic, exaggerated the bed occupancy (general wards 116 forecasted vs 66 observed, ICU 47 forecasted vs 34 observed) and predicted the peak too late (general ward forecast April 9, observed April 8, ICU forecast April 19, observed April 8). After April 5, the dynamic model could be run daily and precision improved with increasing availability of empirical local data. Conclusions: The models provided data-based guidance in the preparation and allocation of critical resources of a university hospital well in advance of the epidemic surge, despite overestimating the service demand. Overestimates should resolve when population contact pattern before and during restrictions can be taken into account, but for now they may provide an acceptable safety margin for preparing during times of uncertainty.